Compare KNDI & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNDI | TLPH |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.8M | 64.7M |
| IPO Year | N/A | 2011 |
| Metric | KNDI | TLPH |
|---|---|---|
| Price | $0.79 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 254.5K | ★ 428.1K |
| Earning Date | 03-13-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,035,613.00 | $28,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14,267.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.78 | $0.38 |
| 52 Week High | $1.81 | $1.57 |
| Indicator | KNDI | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 31.09 | 45.27 |
| Support Level | $0.79 | $1.02 |
| Resistance Level | $0.88 | $1.22 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 1.39 | 38.46 |
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.